AstraZeneca has been removed from Denmark’s COVID-19 vaccine program, and this was officially announced on Wednesday, April 14. With this decision, the region became the first country to completely abandon this brand of coronavirus shots.
Delayed vaccination schedule
As per Reuters, the move will put off Denmark’s scheduled completion of its AstraZeneca vaccination scheme that was initially set to July 25. The new date has been moved to early August, according to health authorities.
This means that everyone who already has vaccination appointments for AstraZeneca vaccine shots will be canceled and rescheduled. For those who have received the first dose, they will not be getting the pulled-out vaccine anymore, but a new brand will be administered as a second dose.
It was added that those who are 16 years old and above could expect to get an offer for vaccination in late June. The individuals who will accept the offer will be inoculated five weeks later, which is in early August.
Why Denmark ditches AstraZeneca
The Danish Health Authority released a statement and cited rare side effects and others as reasons for the decision to stop administering the AstraZeneca vaccine to the citizens. The agency further explained that while the benefits o- taking the shots outweigh the risks, they still chose to discontinue due to the possible link to rare cases of blood clotting. The health authority added that other vaccines are also available in Denmark, so they could just use this.
"Based on the scientific findings, our overall assessment is there is a real risk of severe side effects associated with using the COVID-19 vaccine from AstraZeneca," DHA’s director-general, Søren Brostrøm, said. "We have, therefore, decided to remove the vaccine from our vaccination program."
He went on to explained, "In the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against COVID-19. However, we have other vaccines at our disposal, and the epidemic is currently under control.
Once the administration of COVID-19 vaccines starts again in Denmark, it was said that the Johnson & Johnson brand would be used. In any case, this vaccine was rolled out in Europe and got delayed due to reports of the same blood clotting that was said to have developed in some people who had the AstraZeneca vaccine.


Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
European Stocks Rise as Markets Await Key U.S. Inflation Data
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 



